KB-1206

Volagidemab

Background

Volagidemab is a monoclonal antibody (mAb) that acts as an antagonist to the glucagon receptor (GCGR). Volagidemab specifically targets the GCGR, which is a receptor found on the surface of pancreatic cells. Activation of the GCGR leads to insulin secretion and an increase in blood glucose levels. By blocking the function of the GCGR, Volagidemab reduces insulin secretion and lowers blood glucose levels. Research has shown that Volagidemab significantly decreases fasting blood glucose levels and glycated hemoglobin levels in T1D patients, while also reducing the amount of insulin needed. This makes Volagidemab a potential candidate for the treatment of T1D, as it can help improve blood glucose control and reduce the risk of diabetes-related complications.

Specifications

Catalog Number:
KB-1206
Cell Line Name:
Volagidemab
Price:
0
Host Cell Line:
EXPI-CHO
Target:
GCGR
Species Reactivity:
Human
Application:
FACS
Purification Method:
Affinity purified
Concentration:
>2mg/mL
Purity:
>95% by SDS-PAGE and SEC-HPLC
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Storage:
Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.
Bio Safety Level:
1
Validation:
SDS-PAGE | SEC-HPLC | FACS

References

1.Pettus J, et al. Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial. Nat Med. 2022 Oct;28(10):2092-2099. 2.Wang MY, et al. Glucagon receptor antibody completely suppresses type 1 diabetes phenotype without insulin by disrupting a novel diabetogenic pathway. Proc Natl Acad Sci U S A. 2015 Feb 24;112(8):2503-8.
Please enable JavaScript in your browser to complete this form.